Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Zoledronic acid may have anti-tumour properties
Early evaluations of zoledronic acid suggest a possible direct anti-tumour effect when combined with neoadjuvant chemotherapy in breast cancer treatment, according to data presented at the San Antonio Breast Cancer Symposium.
"Zoledronic acid is primarily targeted to bone and metastasis within the bone marrow microenvironment, but it may also be enhancing the response in the primary breast tumour" said Robert Coleman, M.D., FRCP, professor of medical oncology at the University of Sheffield in the United Kingdom.
Coleman is the lead researcher on the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial, which is evaluating the effect of zoledronic acid on breast cancer. Although the larger AZURE trial is still being evaluated, if the findings in this smaller study are confirmed, the effect could be ìpractice changing,î Coleman said.
The AZURE trial enrolled 3,360 women with stage II/III breast cancer to determine whether treatment with zoledronic acid in addition to adjuvant or neoadjuvant chemotherapy would improve disease outcomes.
Coleman and colleagues performed a retrospective pathology analysis on 205 patients who received neoadjuvant chemotherapy to determine zoledronic acidís impact on the primary tumour.
Zoledronic acid appeared to reduce tumor size from 30 mm in the chemotherapy alone group to 20.5 mm in the combination group. After adjusting for variables like oestrogen receptor status and treatment duration, the difference remained at 42.4 mm in the chemotherapy group and 28.2 mm in the combination group.
The pathological complete response rate was 5.8 percent in the chemotherapy arm and 10.9 percent in the zoledronic acid group.
The number of patients requiring mastectomy was 77.9 percent in the chemotherapy group and 65.3 percent in the combination group.
ìZoledronic acid is currently approved for the treatment of bone metastasis and osteoporosis. If the AZURE trial remains positive, then weíll file for an additional indication,î said Coleman.
More here: 'Zoledronic acid for breast cancer'
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.